当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Chromosome 11q13 markers and D-type cyclins in breast cancer.

Chromosome 11q13 markers and D-type cyclins in breast cancer.

Abstract：

:One in six primary human breast cancers has DNA amplification centered on the cyclin D1 gene (CCND1) on chromosome 11q13. This genetic abnormality is preferentially associated with estrogen-receptor positive tumors and may define a sub-class of patients with an adverse prognosis. Although CCND1 has the credentials of a cellular oncogene, being a target for chromosomal translocation and retroviral integration, the 11q13 amplicon encompasses several other markers and CCND1 is not the only candidate for the key gene on the amplified DNA. To assess their relative importance, we have constructed a physical map of the amplified DNA and compared the extent and frequency of amplification across the region. Since it is likely that the gene providing the selective force for amplification will be expressed at elevated levels, we have also examined expression of both RNA and protein. By these criteria, cyclin D1 remains the strongest candidate for the key oncogene on the amplicon and we are currently investigating the functional consequences of its over-expression.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Peters G,Fantl V,Smith R,Brookes S,Dickson C

doi

10.1007/BF00682720

subject

Has Abstract

pub_date

1995-01-01 00:00:00

pages

125-35

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

33

pub_type

杂志文章,评审

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

    abstract：:In 1973, McGuire and Chamness (In: O'Malley BW and Means AR (ed) Receptors for Reproductive Hormones, Plenum Press) summarized their work on the estrogen receptor in animal and human breast tumors, and in so doing described a target for therapeutic intervention. At that time there were no clinically useful antiestroge...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00713399

    authors： Jordan VC

    更新日期：1995-01-01 00:00:00

  • DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

    abstract：:This is the consensus statement regarding the clinical utility of DNA cytometry in breast cancer from the DNA Cytometry Consensus Conference held in Prout's Neck, Maine, USA, on October 1-4, 1992. Guidelines for clinical DNA cytometry generated at that meeting also appear in this issue of Breast Cancer Research and Tr...

    journal_title：Breast cancer research and treatment

    pub_type： 共识发展会议,杂志文章,评审

    doi：10.1007/BF00666357

    authors： Hedley DW,Clark GM,Cornelisse CJ,Killander D,Kute T,Merkel D

    更新日期：1993-10-01 00:00:00

  • Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses.

    abstract：:We report the establishment of a breast epithelial cell model that undergoes growth arrest at different stages of the cell cycle depending upon the DNA damaging agents encountered. Primary breast epithelial cells from normal reductive mammoplasty were grown in low-calcium culture medium. Free-floating cells under this...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9173-4

    authors： Shen KC,Miller F,Tait L,Santner SJ,Pauley R,Raz A,Tainsky MA,Brooks SC,Wang YA

    更新日期：2006-08-01 00:00:00

  • The prognostic impact of age in different molecular subtypes of breast cancer.

    abstract：:Breast cancer is a heterogeneous entity composed of distinct molecular subgroups with different molecular and clinical features. We analyzed the association between molecular breast cancer subgroups, age at diagnosis, and prognosis in a compilation of publicly available gene expression datasets. Affymetrix gene expres...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3491-3

    authors： Liedtke C,Rody A,Gluz O,Baumann K,Beyer D,Kohls EB,Lausen K,Hanker L,Holtrich U,Becker S,Karn T

    更新日期：2015-08-01 00:00:00

  • PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.

    abstract：:We attempted to develop a highly sensitive and specific method for the detection of circulating tumor DNA (ctDNA) using a digital PCR (dPCR) assay for PIK3CA mutations (i.e., H1047R, E545K, and E542K) in primary breast cancer patients. The sensitivity of the dPCR assay for the mutant alleles was examined using cell li...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3322-6

    authors： Oshiro C,Kagara N,Naoi Y,Shimoda M,Shimomura A,Maruyama N,Shimazu K,Kim SJ,Noguchi S

    更新日期：2015-04-01 00:00:00

  • Mammographic density and breast cancer risk in White and African American Women.

    abstract：:Mammographic density is a strong risk factor for breast cancer, but limited data are available in African American (AA) women. We examined the association between mammographic density and breast cancer risk in AA and white women. Cases (n = 491) and controls (n = 528) were from the Carolina Breast Cancer Study (CBCS) ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2185-3

    authors： Razzaghi H,Troester MA,Gierach GL,Olshan AF,Yankaskas BC,Millikan RC

    更新日期：2012-09-01 00:00:00

  • National consensus recommendations on patient-centered care for ductal carcinoma in situ.

    abstract：PURPOSE:The purpose of this research was to generate recommendations on strategies to achieve patient-centered care (PCC) for ductal carcinoma in situ (DCIS). METHODS:Thirty clinicians (surgeons, medical/radiation oncologists, radiologists, nurses, navigators) who manage DCIS and 32 DCIS survivors aged 18 or older wer...

    journal_title：Breast cancer research and treatment

    pub_type： 共识发展会议,杂志文章,评审

    doi：10.1007/s10549-019-05132-z

    authors： Gagliardi AR,Wright FC,Look Hong NJ,Groot G,Helyer L,Meiers P,Quan ML,Urquhart R,Warburton R

    更新日期：2019-04-01 00:00:00

  • Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

    abstract：:One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a taxane-anthracycline based chemotherapy. Despite largely significant differences in pathological complete response (pCR) in the...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-012-2149-7

    authors： Pernas S,Gil-Gil M,de Olza MO,Gumà A,Climent F,Petit A,Pla MJ,García-Tejedor A,López-Ojeda A,Falo C,Fernandez-Otega A,Mesia C,Pérez-Martin FJ,Urruticoechea A,Germà JR

    更新日期：2012-08-01 00:00:00

  • Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins.

    abstract：:The complexity of breast cancer biology makes it challenging to analyze large datasets of clinicopathologic and molecular attributes, toward identifying the key prognostic features and producing systems capable of predicting which patients are likely to relapse. We applied machine-learning techniques to analyze a set ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0557-0

    authors： Asgarian N,Hu X,Aktary Z,Chapman KA,Lam L,Chibbar R,Mackey J,Greiner R,Pasdar M

    更新日期：2010-06-01 00:00:00

  • The relationship of urinary and plasma androgens to steroid receptors and menopausal status in breast cancer patients and their influence on survival.

    abstract：:The relationships between urinary 11-desoxy-17-oxo steroids (11-DOS), the ratio of 11-DOS to urinary 17-hydroxycorticosteroids (urinary discriminant ratio), plasma levels of the adrenal androgens dehydroepiandrosterone (DHA), DHA sulphate (DHAS), and 7 alpha-hydroxy DHA (7 alpha DHA), and tumour oestrogen receptor (ER...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00665771

    authors： Mason BH,Holdaway IM,Skinner SJ,Kay RG

    更新日期：1994-01-01 00:00:00

  • Endocan as a prognostic biomarker of triple-negative breast cancer.

    abstract：PURPOSE:Triple-negative breast cancer (TNBC) has aggressive characteristics and fewer treatment options than other subtypes. The purpose of this study was to explore prognostic biomarkers for TNBC that can be easily detected from the blood samples. METHODS:MDA-MB-231 and MDA-MB-231BR, a brain metastatic variant of the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4057-8

    authors： Sagara A,Igarashi K,Otsuka M,Kodama A,Yamashita M,Sugiura R,Karasawa T,Arakawa K,Narita M,Kuzumaki N,Narita M,Kato Y

    更新日期：2017-01-01 00:00:00

  • Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations.

    abstract：BACKGROUND:In 2003, for the first time, US breast cancer incidence rates have fallen. Experts argue whether this is due to the reduced uptake of screening mammography or to lower use of Hormone Replacement Therapy (HRT). This study aims to disentangle the respective impact of screening and HRT on age-incidence rates an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9554-3

    authors： Verkooijen HM,Koot VC,Fioretta G,van der Heiden M,Schipper ME,Rapiti E,Peeters PH,Peterse JL,Bouchardy C

    更新日期：2008-02-01 00:00:00

  • Factors influencing the use of extended adjuvant endocrine therapy.

    abstract：PURPOSE:Extending adjuvant endocrine therapy (ET) beyond 5 years has been shown to improve outcomes in breast cancer; however, limited data are available about if and why women pursue extended ET. The primary objective was to estimate the proportion of women who were willing to receive extended ET if recommended by the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05145-8

    authors： Kadakia KC,Kidwell KM,Barton DL,Schott AF,Hayes DF,Griggs JJ,Henry NL

    更新日期：2019-05-01 00:00:00

  • Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.

    abstract：:Brain gray matter alterations have been reported in cross-sectional magnetic resonance imaging (MRI) studies of breast cancer patients after cancer treatment. Here we report the first prospective MRI study of women undergoing treatment for breast cancer, with or without chemotherapy, as well as healthy controls. We hy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1088-4

    authors： McDonald BC,Conroy SK,Ahles TA,West JD,Saykin AJ

    更新日期：2010-10-01 00:00:00

  • Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients.

    abstract：:Relaxin (RLX) is known to induce remodeling of benign stromal tissues through upregulation of matrix metalloproteases (MMPs). Recently, we could show that RLX also induces MMPs in breast cancer cells and enhances in vitro invasiveness. To investigate its potential role for progression of breast cancer in vivo, RLX ser...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000041622.30169.16

    authors： Binder C,Simon A,Binder L,Hagemann T,Schulz M,Emons G,Trümper L,Einspanier A

    更新日期：2004-09-01 00:00:00

  • Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?

    abstract：PURPOSE:We sought to determine if bioimpedance spectroscopy (BIS) measurements can accurately assess changes in breast cancer-related lymphedema (BCRL) in patients undergoing lymphovenous bypass (LVB). METHODS:Patients undergoing LVB for BCRL refractory to conservative treatment from 1/2015 to 12/2018 were identified ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-020-06059-6

    authors： Sutherland A,Wagner JL,Korentager S,Butterworth J,Amin AL,Balanoff CR,Hangge A,Larson KE

    更新日期：2021-01-04 00:00:00

  • Effects of tea consumption and the interactions with lipids on breast cancer survival.

    abstract：PURPOSE:The effect of tea consumption on breast cancer survival remained to be explored. Meanwhile, green tea favorably facilitates lipid metabolisms in breast cancer survivors. This study aimed to examine the effect of tea consumption and the interactions with lipids on breast cancer survival. METHODS:A total of 1551...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05253-5

    authors： Zhang JY,Liao YH,Lin Y,Liu Q,Xie XM,Tang LY,Ren ZF

    更新日期：2019-08-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract：:The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1429-y

    authors： Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期：2011-06-01 00:00:00

  • Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines.

    abstract：:Heregulin (HRG) and 17beta-estradiol (E2) interactions that modulate growth of breast cancer cell lines have recently been demonstrated. We examined the ability of heregulin beta1 (HRGbeta1) and 17beta-estradiol to modulate the biological behavior of estrogen receptor (ER) negative human breast cancer cell lines (AU-5...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006035603635

    authors： Yoo JY,Lessor T,Hamburger AW

    更新日期：1998-09-01 00:00:00

  • Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial.

    abstract：:Results from several randomised mammography screening trials have shown that it is possible to reduce mortality in breast cancer by mammographic screening at least for women above 50 years of age. The purpose of this article is to present data on mortality in breast cancer in study and control groups of the Stockholm ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1005872617944

    authors： Frisell J,Lidbrink E,Hellström L,Rutqvist LE

    更新日期：1997-09-01 00:00:00

  • Tamoxifen aziridine binding to cytosolic proteins from human breast specimens is negatively associated with estrogen receptors, progesterone receptors, pS2, and cathepsin-D.

    abstract：:[3H]Tamoxifen Aziridine ([3H]TAZ) is a derivative of the antiestrogen tamoxifen that covalently labels the Estrogen Receptor (ER), and perhaps other uncharacterized proteins. In a previous article we described that [3H]TAZ binds to a cytosolic protein from human uterine tissues that shares some, but not all, the ER pr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006062510883

    authors： Navarro D,Doreste H,Cabrera JJ,Morales M,Díaz-Chico JC,Díaz-Chico BN

    更新日期：1998-07-01 00:00:00

  • A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.

    abstract：:Cognitive impairment, especially verbal episodic memory and executive function impairments, has been considered to be a possible adverse effect of aromatase inhibitors (AI). This phase III open-label study compared the impact of tamoxifen and AI on verbal episodic memory (Rey auditory verbal learning test-RAVLT) and o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-015-3493-1

    authors： Le Rhun E,Delbeuck X,Lefeuvre-Plesse C,Kramar A,Skrobala E,Pasquier F,Bonneterre J

    更新日期：2015-08-01 00:00:00

  • The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).

    abstract：PURPOSE:In Brazil, the available cancer registries are deficient in number and quality and, hence, little information is known regarding sociodemographic, clinicopathological characteristics, treatment patterns, and outcomes of breast cancer (BC) patients. We performed the AMAZONA III/ GBECAM 0115 study and in this ana...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05831-y

    authors： Rosa DD,Bines J,Werutsky G,Barrios CH,Cronemberger E,Queiroz GS,de Lima VCC,Freitas-Júnior R,Couto JD,Emerenciano K,Resende H,Crocamo S,Reinert T,Van Eyil B,Nerón Y,Dybal V,Lazaretti N,de Cassia Costamilan R,de Andrad

    更新日期：2020-10-01 00:00:00

  • Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.

    abstract：PURPOSE:Homologous recombination (HR)-deficient breast tumors may have genomic alterations that predict response to treatment with PARP inhibitors and other targeted therapies. METHODS:Comprehensive molecular profiles of 4647 breast tumors performed at Caris Life Sciences using 592-gene NGS were reviewed to identify s...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05849-2

    authors： Heeke AL,Xiu J,Elliott A,Korn WM,Lynce F,Pohlmann PR,Isaacs C,Swain SM,Vidal G,Schwartzberg LS,Tan AR

    更新日期：2020-11-01 00:00:00

  • Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases.

    abstract：:The mitochondrial DNA (mtDNA) 4977-bp deletion (DeltamtDNA(4977) mutation) is one of the most frequently observed mtDNA mutations in human tissues and may play a role in carcinogenesis. Only a few studies have evaluated DeltamtDNA(4977) mutation in breast cancer tissue, and the findings have been inconsistent, which m...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9613-9

    authors： Ye C,Shu XO,Wen W,Pierce L,Courtney R,Gao YT,Zheng W,Cai Q

    更新日期：2008-04-01 00:00:00

  • Growth kinetics of four human breast carcinomas grown in nude mice.

    abstract：:The immune-deficient nude mouse with human tumor xenografts is an appropriate model system for performing detailed growth kinetic examinations. In the present study one estrogen and progesterone receptor-negative (T60) and three receptor-positive (Br-10, MCF-7, T61) human breast cancer xenografts in nude mice were inv...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01810740

    authors： Spang-Thomsen M,Rygaard K,Hansen L,Halvorsen AC,Vindeløv LL,Brünner N

    更新日期：1989-11-01 00:00:00

  • Predictors of interobserver agreement in breast imaging using the Breast Imaging Reporting and Data System.

    abstract：:The Breast Imaging Reporting and Data System (BI-RADS) was introduced in 1993 to standardize the interpretation of mammograms. Though many studies have assessed the validity of the system, fewer have examined its reliability. Our objective is to identify predictors of reliability as measured by the kappa statistic. We...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-010-0770-x

    authors： Antonio AL,Crespi CM

    更新日期：2010-04-01 00:00:00

  • Design of preparative regimens for stem cell transplantation in breast cancer.

    abstract：:We have evaluated tandem cycles of a tri-drug combination, termed CVP (cyclophosphamide, etoposide [VP-16], and cisplatin [Platinol]), at four levels in more than 300 patients with various types of tumors. Tandem CVP appears to be at least therapeutically equivalent to alternatives. A second potentially non-cross-resi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00668354

    authors： Spitzer G,Adkins D,Dunphy F,Petruska P,Spencer V,Velasquez W

    更新日期：1993-01-01 00:00:00

  • Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.

    abstract：:Triple-negative breast cancers lack estrogen receptor α (ERα), progesterone receptor, and do not overexpress human epidermal growth factor receptor 2 (Her-2). They are neither susceptible to endocrine therapy nor to a therapy using the anti-Her-2 antibody, trastuzumab. Therefore, an efficient targeted therapy is warra...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-1968-x

    authors： Girgert R,Emons G,Gründker C

    更新日期：2012-07-01 00:00:00

  • Assessment of PARP4 as a candidate breast cancer susceptibility gene.

    abstract：PURPOSE:PARP4 has been proposed as a candidate breast cancer susceptibility gene. However, its function and involvement in breast carcinogenesis is unclear. We sought to determine the variant frequency of PARP4 in BRCA-negative women referred for genetic testing from Singapore and to perform functional analyses of PARP...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05286-w

    authors： Prawira A,Munusamy P,Yuan J,Chan CHT,Koh GL,Shuen TWH,Hu J,Yap YS,Tan MH,Ang P,Lee ASG

    更新日期：2019-08-01 00:00:00